328918-86-1

Upstream product

• 4124-41-8 p-toluenesulfonylanhydride 
• 328918-85-0 2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethanol 
• 98-80-6 phenylboronic acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 328918-84-9 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 328918-82-7 2-(4-bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-83-8 [2-(4-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 328918-81-6 2-(4-bromophenyl)-4-(chloromethyl)-5-methyl-1,3-oxazole 
• 328918-80-5 4,5-dimethyl-2-(4-bromophenyl)-oxazole oxide 

Downstream Products

• 328918-88-3 2-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid ethyl ester 
• 698347-45-4 3-{4-[2-(2-biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]phenyl}-2-methyl-2-phenoxypropionic acid ethyl ester 
• 853260-27-2 3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-p-tolyloxy-propionic acid ethyl ester 
• 853260-43-2 3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-tert-butyl-phenoxy)-2-methyl-propionic acid ethyl ester 
• 478541-69-4 3-[4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-(isopropoxycarbonylamino-methyl)-phenyl]-propionic acid tert-butyl ester 
• 853076-92-3 5-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-8-(2-methoxycarbonyl-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 401468-49-3 3-{4-[2-(2-Biphenyl-4-yl-5-methyloxazol-4-yl)ethoxy]-phenyl}-2-methyl-2-phenoxypropionic acid 
• 401468-89-1 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-(4-tert-butylphenoxy)-propionic acid 
• 401469-37-2 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-m-tolyloxy-propionic acid 
• 401469-32-7 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)ethoxy]-phenyl}-2-(3,4-difluoro-phenoxy)-2-methyl-propionic acid 
• 401469-24-7 2-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-benzyl}-2-phenoxy-butyric acid 
• 1027935-57-4 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(3-tert-butyl-phenoxy)-2-methyl-propionic acid 
• 401469-41-8 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-fluoro-phenoxy)-2-methyl-propionic acid 
• 401469-15-6 3-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(3,4-dimethyl-phenoxy)-2-methyl-propionic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands

PPAR ligands with varied subtype selectivity have been synthesized using an achiral aminomethyl dihydrocinnamate template. Several compounds in this series have demonstrated potent plasma glucose and triglyceride lowering capability in rodent models of type 2 diabetes.

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis

To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b

Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Propionic acid derivative 8, which was designed and synthesized based on putative pharmacophores of known PPARγ- and PPARα-selective compounds, exhibits potent dual PPARα/γ agonist activity as demonstrated by in vitro binding and dose overlap in the newly